Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Fritzinger

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
The Journal of Biological Chemistry|May 8, 2004
Structure and function of recombinant cobra venom factorMichael A Kock, Brian E Hew, Holger Bammert, et al.
Molecular Immunology|September 15, 2009
Humanized cobra venom factor decreases myocardial ischemia-reperfusion injuryW Brian Gorsuch, Benjamin J Guikema, David C Fritzinger, et al.
Molecular Immunology|March 12, 2018
Absence of a neutralizing antibody response to humanized cobra venom factor in miceMathieu Ing, Brian E Hew, David C Fritzinger, et al.
Developmental and Comparative Immunology|September 2, 2008
Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletionDavid C Fritzinger, Brian E Hew, Mike Thorne, et al.
Advances in Experimental Medicine and Biology|August 17, 2010
Complement depletion with humanized cobra venom factor in a mouse model of age-related macular degenerationDavid C Fritzinger, Robin Dean, Carol Meschter, et al.
Blood|October 7, 2009
Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo modelSiao-Yi Wang, Suresh Veeramani, Emilian Racila, et al.
The EMBO Journal|July 4, 2009
Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complexBert J C Janssen, Lucio Gomes, Roman I Koning, et al.
Haematologica|November 18, 2017
Complement C3 is a novel modulator of the anti-factor VIII immune responseJulie Rayes, Mathieu Ing, Sandrine Delignat, et al.
Advances in Experimental Medicine and Biology|November 26, 2008
Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agentsDavid C Fritzinger, Brian E Hew, June Q Lee, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The Journal of Biological Chemistry|May 8, 2004
Structure and function of recombinant cobra venom factorMichael A Kock, Brian E Hew, Holger Bammert, et al.
Molecular Immunology|September 15, 2009
Humanized cobra venom factor decreases myocardial ischemia-reperfusion injuryW Brian Gorsuch, Benjamin J Guikema, David C Fritzinger, et al.
Molecular Immunology|March 12, 2018
Absence of a neutralizing antibody response to humanized cobra venom factor in miceMathieu Ing, Brian E Hew, David C Fritzinger, et al.
Developmental and Comparative Immunology|September 2, 2008
Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletionDavid C Fritzinger, Brian E Hew, Mike Thorne, et al.
Advances in Experimental Medicine and Biology|August 17, 2010
Complement depletion with humanized cobra venom factor in a mouse model of age-related macular degenerationDavid C Fritzinger, Robin Dean, Carol Meschter, et al.
Blood|October 7, 2009
Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo modelSiao-Yi Wang, Suresh Veeramani, Emilian Racila, et al.
The EMBO Journal|July 4, 2009
Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complexBert J C Janssen, Lucio Gomes, Roman I Koning, et al.
Haematologica|November 18, 2017
Complement C3 is a novel modulator of the anti-factor VIII immune responseJulie Rayes, Mathieu Ing, Sandrine Delignat, et al.
Advances in Experimental Medicine and Biology|November 26, 2008
Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agentsDavid C Fritzinger, Brian E Hew, June Q Lee, et al.
Pageof 2